Across TCGA pan-cancer cohorts, RPL9P21 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RPL9P21’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RPL9P21 RNA is repressed in tumor relative to normal tissue. In most cancer types RPL9P21 is over-expressed in tumor, although a few such as BRCA and UCEC show the opposite, repressed pattern.

BRCA, KIRC, and UCEC are the cancer types where RPL9P21 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL9P21 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	All	−0.171	<.001	6	view →
KIRC	All	All	+0.114	.001	3	view →
UCEC	All	All	−0.572	.001	2	view →
THCA	Female	II,III,IV	+0.432	.015	2	view →
CHOL	Female	All	+0.290	.021	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: RPL9P21 RNA expression & survival · all RPL9P21 data types